Term Efficacy Of Cetuximab Joint MFOLFOX6Treatment Of Colorectal Liver Metastases

Objective:The liver is the most common sites of metastases in advanced colorectal cancer.For patients with liver metastases, radical resection is the only possible means of cure.But merely a few patients with liver metastases at diagnosis who underwent radical livermetastases resection, more patients can not get the chance of operation.In recent years a large number of molecular targeted drugs combined withchemotherapy for colorectal cancer clinical trials have shown the advantages of targetedtherapy.Cetuximab is a monoclonal antibody against epidermal growth factor receptor(EGFR), can be specifically combined with EGFR and inhibit tumor cell proliferationby blocking the growth factor combination with EGFR, and promote tumor cellapoptosis and inhibition of tumor angiogenesis and tumor metastasis. The current studyfound that the cetuximab the joint mFOLFOX6chemotherapy treatment of colorectalliver metastases showed good efficacy.In this study, the KRAS wild-type unresectable colorectal liver metastases usingmFOLFOX-6regimen in combination with cetuximab for first-line chemotherapy, theobserved increase targeted drugs could further improve the curative resection rate,evaluation of cetuximabthe efficacy and safety of the drug.Methods:22cases of colorectal liver metastases patients, divided into two treatment groups.The Joint Group of11patients, application of Cetuximab the United mFOLFOX6program, colorectal liver metastases in patients with treatment; control group of11patients for the same period in colorectal liver metastases in patients with single mFOLFOX6program of chemotherapy. The observed clinical efficacy of two programs,the R0resection rate, compare the efficiency and cetuximab the safety evaluation.Results:Total joint group with the control group rate (RR) consists of54.5%and36.4%(P=0.670), disease control rate (DCR) was72.7%and63.6%, respectively (P=0.500);but look at the value the combination group compared withcontrol group in terms ofefficiency and disease control rate advantage, but the difference was not statisticallysignificant. R0resection rates were27.3%，0%(P=0.107), the combination groupthan the control group, but the difference was not statistically significant. The twogroups of patients with major adverse reactions are nausea, vomiting, diarrhea,allergic-like reaction, neurotoxicity, bone marrow suppression, acne-like rash; mostly I-II degree, III-IV degree rare. The only acne-like rash difference between the twogroups was statistically significant, the incidence of combined group81.8%,respectively, control group9.1%(P=0.001), other aspects of adverse reactions was nosignificant difference, said minthi properly infliximab does not add mFOLFOX6chemotherapy toxicity.Conclusion:Cetuximab the joint mFOLFOX6chemotherapy compared with ColorectalHepatic Metastases from high R0resection alone mFOLFOX6program, and will notincrease the side effects of chemotherapy, is one of the options recommended treatmentof colorectal liver metastases.